Price movement over the last 24 hours
Apple Inc vs Baxter International Inc — how do they compare? Apple Inc trades at $313.17 (market cap $4.56T), while Baxter International Inc trades at $21.93 (market cap $11.81B). The key difference: Apple Inc is far larger — about 386.1× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.
| AAPL | BAX | |
|---|---|---|
Market Cap | $4.56T | $11.81B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $30.66 |
52-Week Low | $202.38 | $15.80 |
Enterprise Value | $4.58T | $19.48B |
Dividend Yield | 0.35% | 0.87% |
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.27, up 0.2% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, though valuation ratios like P/E of 37.61 are elevated. Recent news highlights AI integration via Alphabet's Gemini and ongoing retail adjustments, including store closures amid union disputes.
Outlook remains positive with analyst consensus targeting $329.62, but risks include high valuation sensitivity and competitive pressures. Earnings have consistently beaten estimates, supporting growth potential, yet investors should monitor margin pressures and regulatory scrutiny in key markets.
Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.
Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →